13 February 2013
Aqua Bio Technology ASA (Oslo Axess: ABT) today announced its 2012 financial results. The
Company had its commercial breakthrough in 2012 and posted revenues of NOK 20.3 million
for the year. ABT’s revenues the year before were NOK 0.5 million.
Contracts with two US based customers are the main reason for the commercial success. Aqua Bio
Technology’s lead ingredient Aquabeautine XLTM is now included in new skincare products being
Aqua Bio Technology’s EBITDA for 2012 ended at NOK 8.0 million, compared to NOK -8.1 million in
2011. The company’s net result for the year was NOK 0.9 million, against NOK -13.5 the previous
For the fourth quarter alone, ABT posted revenues of NOK 3.4 million and an EBITDA of NOK 0.2
million. Net result for the fourth quarter was NOK -2.7 million.
The contracts secure ABT total revenues of more than NOK 120 million in the period 2012-2017, in
the form of exclusivity and minimum royalty payments for Aquabeautine XLTM. Product sales are
expected to provide additional revenues.
Aqua Bio Technology launched three new products in 2012. Like Aquabeautine XLTM these are
sustainable, marine based ingredients for cosmetics. The new products have been well received by
the market. The cosmetics industry is constantly seeking natural and sustainable alternatives to the
petroleum based ingredients currently used in cosmetics. ABT’s range of ingredients is entirely marine
based and holds unique features, documented through extensive trials.
For further information, please call Arvid Lindberg, CEO, telephone +47 9824 5410
Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the
international cosmetic and skin care industry. ABT's ingredients Aquabeautine XL, Dermaclarine and Beauty
Propelline are marine solutions derived from the hatching fluid of salmon, while Oceanx Oil in Serum is based
on extract from seaweed. ABT is listed on the Oslo Stock Exchange’s Axess market.